| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g | |||
| Other Sizes |
| Targets |
Bentiamine acts as a prodrug for thiamine. After absorption, it is converted to thiamine, which is an essential cofactor for several enzymes involved in carbohydrate metabolism, including pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase. These enzymes are critical for energy production, the pentose phosphate pathway, and the synthesis of neurotransmitters.
|
|---|---|
| ln Vitro |
Dibenzoyl Thiamine is a thiamine derivative made up of thiamine and benzoic acid. It is not degraded by neuraminidase (a thiamine-degrading enzyme), making it more suited for food processing than thiamine hydrochloride [1].
In vitro, bentiamine is converted to thiamine in the presence of appropriate enzymes or in cell culture. The resulting thiamine acts as a cofactor for its target enzymes. The activity of transketolase, a thiamine-dependent enzyme, can be measured in cell extracts or in whole cells after treatment with bentiamine to assess its ability to provide active thiamine. |
| ln Vivo |
Dibenzoyl Thiamine was shown to have no particular harmful effects in a 6-month chronic toxicity investigation in male Wistar rats fed at food levels up to 1000 ppm. Dibenzoyl Thiamine has neither embryotoxic nor teratogenic effects, according to rat teratogenicity tests. Dibenzoyl Thiamine is not mutagenic, according to dominant lethality experiments, in vivo cytogenetic testing, and mutagenicity tests conducted in bacterial systems. Benzoic acid and vitamin Br are produced during the metabolism of dibenzoyl thiamine; the benzoic acid portion is nearly all eliminated in the urine as hippuric acid [1].
In vivo, bentiamine is used as a nutritional supplement to treat or prevent thiamine deficiency. It is often used in Japan and other Asian countries for the treatment of conditions such as beriberi, Wernicke-Korsakoff syndrome, and other neurological disorders associated with thiamine deficiency. Its improved bioavailability makes it more effective than water-soluble thiamine salts. |
| Enzyme Assay |
The in vitro enzyme activation assay for bentiamine involves measuring the activity of a thiamine-dependent enzyme, such as transketolase, after incubation with bentiamine. The enzyme is incubated with its substrate (e.g., ribose-5-phosphate) in the presence of bentiamine, and the formation of the product (e.g., sedoheptulose-7-phosphate) is measured to assess the activation of the enzyme.
|
| Cell Assay |
In vitro cellular assays for bentiamine are performed on cultured cells that are deficient in thiamine. Cells are treated with bentiamine, and the levels of thiamine diphosphate (the active form) are measured by HPLC. The restoration of cell viability or the activity of thiamine-dependent enzymes is used to assess the efficacy of bentiamine as a thiamine source.
|
| Animal Protocol |
In vivo animal experiments for bentiamine are conducted in animal models of thiamine deficiency. Rats are fed a thiamine-deficient diet to induce deficiency. Bentiamine is then administered orally, and the restoration of body weight, neurological function, and thiamine levels in tissues is measured to evaluate its efficacy.
|
| ADME/Pharmacokinetics |
Bentiamine is a lipid-soluble thiamine derivative with high bioavailability. After oral administration, it is rapidly absorbed from the gastrointestinal tract. It is converted to thiamine in the body, primarily in the liver and intestines. The thiamine is then distributed to tissues and converted to its active cofactor forms, thiamine diphosphate (TDP) and thiamine triphosphate (TTP). It is excreted in the urine.
|
| Toxicity/Toxicokinetics |
Bentiamine is generally considered safe and well-tolerated. Thiamine and its derivatives have very low toxicity, as excess amounts are excreted in the urine. No significant adverse effects have been reported with the use of bentiamine at recommended doses. Allergic reactions are rare. It is safe for use in pregnancy and lactation.
|
| References |
[1]. Heywood R, et al. Tumorigenic and toxic effect of O,S-dibenzoyl thiamine hydrochloride in prolonged dietaryadministration to rats. Toxicol Lett. 1985 Jul;26(1):53-8
|
| Additional Infomation |
Dibenzoylthioamine is a benzoic acid ester.
Bentiamine is marketed under various brand names, including Alinamin and Benlipoid. It is widely used as a dietary supplement and as a therapeutic agent for thiamine deficiency in many countries, particularly in Asia. Its improved lipophilicity allows it to be better absorbed and to cross the blood-brain barrier more effectively than water-soluble thiamine. It is available in oral and injectable formulations. |
| Molecular Formula |
C26H26N4O4S
|
|---|---|
| Molecular Weight |
490.58
|
| Exact Mass |
490.167
|
| CAS # |
299-88-7
|
| PubChem CID |
3036235
|
| Appearance |
White to off-white solid powder
|
| Density |
1.291g/cm3
|
| Boiling Point |
718.2ºC at 760mmHg
|
| Melting Point |
173ºC
|
| Flash Point |
388.1ºC
|
| Vapour Pressure |
1.78E-20mmHg at 25°C
|
| Index of Refraction |
1.639
|
| LogP |
5.594
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
35
|
| Complexity |
750
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C(C1C([H])=C([H])C([H])=C([H])C=1[H])=O)/C(/C([H])([H])C([H])([H])OC(C1C([H])=C([H])C([H])=C([H])C=1[H])=O)=C(/C([H])([H])[H])\N(C([H])=O)C([H])([H])C1=C([H])N=C(C([H])([H])[H])N=C1N([H])[H]
|
| InChi Key |
AZJUFRDUYTYIHV-NKFKGCMQSA-N
|
| InChi Code |
InChI=1S/C26H26N4O4S/c1-18(30(17-31)16-22-15-28-19(2)29-24(22)27)23(35-26(33)21-11-7-4-8-12-21)13-14-34-25(32)20-9-5-3-6-10-20/h3-12,15,17H,13-14,16H2,1-2H3,(H2,27,28,29)/b23-18-
|
| Chemical Name |
Benzenecarbothioic acid, S-(2-(((4-amino-2-methyl-5-pyrimidinyl)methyl)formylamino)-1-(2-(benzoyloxy)ethyl)-1-propenyl) ester
|
| Synonyms |
DibenzoylthiamineBentiamine CCRIS1339Bentiamina CCRIS-1339Bentiaminum
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~101.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0384 mL | 10.1920 mL | 20.3840 mL | |
| 5 mM | 0.4077 mL | 2.0384 mL | 4.0768 mL | |
| 10 mM | 0.2038 mL | 1.0192 mL | 2.0384 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
